Search

Displaying results 2021 - 2030 of 7687 in total
  1. Drug

    Durvalumab

    go.drugbank.com/drugs/DB11714
    ApprovedInvestigational

    It was granted accelerated approval by the FDA in May 2017 [A192807] for the treatment of selected patients with locally advanced or metastatic urothelial carcinoma. … [A192789,L12627] On March 27, 2020, durvalumab was approved by the FDA for use in combination with [etoposide] and either [carboplatin] or [cisplatin] as first-line treatment of patients with extensive-stage

  2. Drug

    Sotagliflozin

    go.drugbank.com/drugs/DB12713
    ApprovedInvestigational

    [L39739] On March 22, 2022, the marketing authorization of sotagliflozin for the treatment of type 1 diabetes mellitus was withdrawn by the EMA due to commercial reasons. … [L46616] In May 2023, sotagliflozin was approved by the FDA to reduce the risk of cardiovascular death and heart failure in patients with high risk factors.[]

  3. Drug

    Hexachlorophene

    go.drugbank.com/drugs/DB00756
    ApprovedWithdrawn

    It is mainly used in soaps and creams and is an ingredient of various preparations used for skin disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p797)

  4. Drug

    Etrasimod

    go.drugbank.com/drugs/DB14766
    ApprovedInvestigational

    [A261831] Etrasimod was approved on October 13, 2023, by the FDA under the brand name VELSIPITY for the treatment of adults with moderately to severely active ulcerative colitis. … [A261826] In fact, it has been observed that antigen-activated T cells within peripheral lymphoid organs can transiently downregulate S1P receptor levels to facilitate immune cells trafficking into the

  5. Drug

    Buformin

    go.drugbank.com/drugs/DB04830
    ApprovedWithdrawn

    It was withdrawn from the market in most countries due to a high risk of causing lactic acidosis. … Buformin is an anti-diabetic drug of the biguanide class, chemically related to metformin and phenformin.

  6. Drug

    Rimantadine

    go.drugbank.com/drugs/DB00478
    Approved

    An RNA synthesis inhibitor that is used as an antiviral agent in the prophylaxis and treatment of influenza.

  7. Drug

    Medifoxamine

    go.drugbank.com/drugs/DB13219
    Approved

    Medifoxamine was marketed as an atypical antidepressant, with anxiolyitc properties in France, Spain, and Morrocco in the 1990s but was later withdrawn from the market due to it causing cases of hepatotoxicity

  8. Drug

    Potassium

    go.drugbank.com/drugs/DB14500
    ApprovedInvestigational

    They are available in an assortment of tablet, injection, and other forms, depending on the setting and condition being treated. … Potassium is an essential nutrient, like [Calcium] and [Magnesium]. It was identified as a shortfall nutrient by the 2015-2020 Advisory Committee of Dietary Guidelines for Americans.

    Mixtures: Liquid Opti-minplex +d, Multi Mega Minerals With Vitamin D
  9. Drug

    Magaldrate

    go.drugbank.com/drugs/DB08938
    ApprovedInvestigationalWithdrawn

    Magaldrate is an antacid drug used for the treatment of esophagitis, duodenal and gastric ulcers, and gastroesophageal reflux. Magaldrate has been discontinued in the US market.

    Mixtures: M A L D I M, NESAFLUX DUO
  10. Drug

    Sutimlimab

    go.drugbank.com/drugs/DB14996
    ApprovedInvestigational

    [A245144] It received FDA approval in February 2022, under the brand name Enjamyo (sutimlimab-jome), becoming the first approved therapy for patients with CAD. … [A245159] Pharmacologic strategies have included the targeting of B-cells with agents like [rituximab], as well as targeting of the complement system with drugs like [eculizumab], an anti-C5 mAb, and [